Online inquiry

IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5264MR)

This product GTTS-WQ5264MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5264MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8112MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ7144MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ14383MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ10469MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ7692MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ14167MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ13002MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ12765MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-52M51
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW